Ye et al. developed a synergistic immunotherapy strategy to treat melanoma by locally targeting the immunoinhibitory receptor PD-1 and immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) through an MN-based transdermal delivery method 152. This evidence concerns the gene PDCD1 and melanoma.